Company / Cash & Equivalents
MARIMED INC. Cash & Equivalents History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$7.3M
FY2024
5-year range
$7.3M / $29.7M
FY2020-FY2024
Trend
-50.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 9 years, ranging from $569,356 in FY2016 to $30M in FY2021.
Based on SEC 10-K filings.
$7M in FY2024 with a 5-year CAGR of +58.0%.
Declined from $10M to $7M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -37.4%
- 5-Year CAGR
- +58.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +58.0%, indicating consistent growth.
- In FY2024, cash & equivalents decreased 50.3% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $7.3M | -50.3% |
| FY2023 | $14.6M | +50.4% |
| FY2022 | $9.7M | -67.2% |
| FY2021 | $29.7M | +889.7% |
| FY2020 | $3.0M | +306.0% |
| FY2019 | $738.7K | -82.0% |
| FY2018 | $4.1M | +218.1% |
| FY2017 | $1.3M | +126.6% |
| FY2016 | $569.4K | +253.9% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026